Thromboembolism and Pancreatic Cancer

  • Andre Luiz De Souza Department of Hematology and Oncology, Tufts Medical Center. Boston, MA, USA
  • Muhammad Wasif Saif Department of Hematology and Oncology, Tufts Medical Center. Boston, MA, USA
Keywords: Cohort Studies, Incidence, Pancreatic Neoplasms, Venous Thromboembolism


Venous thromboembolism (VTE) is a frequent event in the clinical course of patients with exocrine pancreatic cancer; studies have been designed to evaluate the role of prophylactic anticoagulation in this ominous disease. Searching for the molecular basis of thrombosis in cancer, Bozkurt et al. present in the Abstract #e22049 the result of their investigation on the frequency of inherited and carcinogenesis-acquired proteins in oncologic patients with and without venous thromboembolism. From the bedside, Muñoz Martin et al. present in the Abstract #e15187 their work on the incidence of venous thromboembolism in patients with exocrine pancreatic cancer and the role of the established Khorana score in predicting symptomatic and incidental venous thromboembolism. At last, Cella et al. in the Abstract #e20625 expand the predictor landscape from the Khorana score to other risk factors for venous thromboembolism, refining the selection of oncologic patients who can benefit from prophylactic anticoagulation.

Image: Thrombus


Download data is not yet available.


Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B, Brilhante D, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost. 2013; 11(1): 56-70. [PMID:23217107]

Lyman GH, Eckert L, Wang Y, Wang H, Cohen A. Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis. Oncologist. 2013; 18(12): 1321-9. [PMID:24212499]

Pabinger I, Ay C. Risk of venous thromboembolism and primary prophylaxis in cancer. Should all patients receive thromboprophylaxis? Hamostaseologie. 2012; 32(2): 132-137. [PMID:21822526]

Habib M, Saif MW. Thromboembolism and anticoagulation in pancreatic cancer. JOP. 2013; 14(2): 135-7. [PMID:23474555]

Pabinger I, Thaler J, Ay C. Biomarkers for prediction of venous thromboembolism in cancer. Blood. 2013; 122(12): 2011-8. [PMID:23908470]

Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 2005; 104(12): 2822-2829. [PMID:16284987]

Connolly GC, Khorana AA, Kuderer NM, Culakova E, Francis CW, Lyman GH. Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thromb Res. 2010; 126(2): 113-118. [PMID:20684071]

Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008; 111(10): 4902-4907. [PMID:18216292]

Zakai NA, Wright J, Cushman M. Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score. J ThrombHaemost. 2004; 2(12): 2156-2161. [PMID:15613021]

Thaler J, Koder S, Kornek G, Pabinger I, Ay C. Microparticle-associated tissue factor activity in patients with metastatic pancreatic cancer and its effect on fibrin clot formation. Transl Res. 2014; 163(2): 145-50. [PMID:23973167]

Geddings JE, Mackman N. Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood. 2013; 122(11): 1873-80. [PMID:23798713]

Pelzer U, Hilbig A, Stieler JM, Bahra M, Sinn M, Gebauer B, Dörken B, RiessH. Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial. BMC Cancer. 2014; 14: 204. [PMID:24641937]

Nakchbandi W, et al. Prospective study on warfarin and regional chemotherapy in patients with pancreatic carcinoma. J Gastrointestin Liver Dis. 2008; 17(3): 285-90. [PMID:18836621]

Icli F, Akbulut H, Utkan G, Yalcin B, Dincol D, Isikdogan A, Demirkazik A, et al. Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer. J Surg Oncol. 2007; 95(6): 507-12. [PMID:17192920]

Bozkurt M, Okutur K, Aydin K, et al. The impact of prothrombotic mutations, PSGL-1 VNTR polymorphism, tissue factor, and soluble P-selectin on venous thromboembolism in cancer patients with adenocarcinoma. J Clin Oncol 32, 2014 (suppl; abstr e22049)

Muñoz Martin AJ, Adrian SG, Luisa Sánchez Lorenzo LS, et al. Incidence of incidental and symptomatic venous thromboembolism (VTE) and Khorana’s score in ambulatory pancreatic cancer patients receiving chemotherapy. Clin Oncol 32, 2014 (suppl; Abstract #e15187)

Trinh VQ, Karakiewicz PI, Sammon J, Sun M, Sukumar S, Gervais MK, Shariat SF, et al. Venous thromboembolism after major cancer surgery: temporal trends and patterns of care. JAMA Surg. 2014; 149(1): 43-9. [PMID:24197279]

Trinh VQ, Karakiewicz PI, Sammon J, Sun M, Sukumar S, Gervais MK, et al. Venous thromboembolism after major cancer surgery: temporal trends and patterns of care. JAMA Surg 2014; 149(1):43-9. [PMID:24197279]

How to Cite
De SouzaA., & SaifM. (2014). Thromboembolism and Pancreatic Cancer. JOP. Journal of the Pancreas, 15(4), 292-294.
Highlights from the “50th ASCO Annual Meeting 2014”. Chicago, IL, USA. May 30 - June 3, 2014